AstraZeneca AZD9291 Mechanism of Action

First Page		Document Content
Date: 2014-05-12 12:58:35 Oncology Lung cancer Biology Epidermal growth factor receptor Non-small-cell lung carcinoma ErbB Tyrosine kinase Tyrosine-kinase inhibitor Organofluorides Oncogenes Tyrosine kinase receptors Medicine		AstraZeneca AZD9291 Mechanism of Action Add to Reading List Source URL: www.ncats.nih.gov Download Document from Source Website File Size: 107,03 KB Share Document on Facebook

	UNDERSTANDING IN VIVO ROLES OF ELKS IN INNATE IMMUNITY Identification of ELKS gene In papillary thyroid carcinoma tissue samples of Japanese patients, tyrosine kinase domain of proto-oncogene RET was found to be fused to DocID: 1sBYn - View Document
	SUPPLEMENTARY INFORMATION: Specificity and mechanism-‐ of-‐action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) 1. Deter DocID: 1rQNF - View Document
	Cytoplasmic Tyrosine Kinases SRC, YES, FYN, LYN, LCK, BLK, HCK, FGR, YRK SH3 SH2 DocID: 1rO3r - View Document
	A conserved protonation-dependent switch controls drug binding in the Abl kinase Yibing Shana, Markus A. Seeligerb, Michael P. Eastwooda, Filipp Frankb, Huafeng Xua, Morten Ø. Jensena, Ron O. Drora, John Kuriyanb,1, and DocID: 1rq9v - View Document
	Microsoft Word - abstracts_compiled.doc DocID: 1rn3E - View Document